There was a recent randomized double-blind clinical trial study in which 1800mg/day of NAC or N-acetylcysteine was used to treat patients with SLE.
N-acetylcysteine (NAC) is a drug approved by the Food and Drug Administration (FDA) and recognized by the World Health Organization (WHO) as an essential drug, which is used for the treatment of acetaminophen overdose. It also functions as an antioxidant as well. Both groups of patients were taking conventional lupus medications. One group of patients in the study took NAC while the other group did not have NAC. The results of this study show that lupus disease activity in the NAC group significantly decreased after three months of treatment including the BILAG and SLEDAI scores. The BILAG and SLEDAI scores are disease activity scores for lupus.
- Abbasifard M, Khorramdelazad H, Rostamian A, Rezaian M, Askari PS, Sharifi GTK, Parizi MK, Sharifi MTK, Najafizadeh SR. Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study. Trials. 2023 Feb 21;24(1):129. doi: 10.1186/s13063-023-07083-9. PMID: 36810107; PMCID: PMC9945717.